Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: Vasodilator capacity and cellular mechanisms

Circulation

Volumn 103, Issue 4, 2001, Pages 544-548

  Rimensberger, Peter C ^a,b   Spahr Schopfer, Isabelle ^a,b   Berner, Michel ^a,b   Jaeggi, Edgar ^a,b   Kalangos, Afksendiyos ^a,b   Friedli, Beat ^a,b   Beghetti, Maurice ^a,b,c  

^a Hopital des Enfants   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Hopital des Enfants Hopitaux universitaires de Geneve   (Switzerland)

Author keywords

Heart defects, congenital; Hypertension, pulmonary; Nitric oxide; Prostaglandins; Vasodilatation

Indexed keywords

CYCLIC AMP; CYCLIC GMP; ILOPROST; NITRIC OXIDE;

ARTICLE; CHILD; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; CYCLIC AMP BLOOD LEVEL; HUMAN; INFANT; LONG TERM CARE; LUNG VASCULAR RESISTANCE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTEMIC VASCULAR RESISTANCE; VASODILATATION;

EID: 0035969984     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.4.544     Document Type: Article

References (30)

1. Inhaled nitric oxide in congenital heart disease
2. Pulmonary vasodilator effects of 12 and 60 parts per million inhaled nitric oxide in children with ventricular septal defect
3. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease
4. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing
5. 2
6. Pulmonary vascular response to prostaglandins
7. 2) versus inhaled nitric oxide in adult respiratory distress syndrome
8. Selective pulmonary vasodilatation by inhaled prostacyclin in a newborn with congenital heart disease and cardiopulmonary bypass
9. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension
10. Inhaled prostacyclin in the treatment of pulmonary hypertension
11. Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants
12. Physical properties of aerosolized immunoglobulin for inhalation therapy
13. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension
14. Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension
15. Pulmonary microvascular responses to inhaled prostacyclin, nitric oxide, and their combination in anesthetized cats
16. Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension
17. Acute effect of oral prostacyclin and inhaled nitric oxide on pulmonary hypertension in children
18. Oral prostacyclin enhances the pulmonary vasodilatory effect of nitric oxide in children pulmonary hypertension
19. Inhaled nitric oxide versus inhaled prostacyclin and intravenous versus inhaled prostacyclin in acute respiratory failure with pulmonary hypertension in piglets
20. The nitric oxide and cGMP signal transduction system: Regulation and mechanism of action
21. Interrelationships of cyclic GMP, inositol phosphates, and calcium
22. 2 inhibit ET-1 secretion from endothelial cells by stimulating particulate guanylate cyclase
23. 2) in healthy lambs: Effects on tracheal, bronchial, and alveolar morphology
24. 2) for 8 hours does not produce signs of acute pulmonary toxicity in healthy lambs
25. Rebound pulmonary hypertension after withdrawal from inhaled nitric oxide
26. Rebound pulmonary hypertension after inhalation of nitric oxide
27. Pressurized aerosol versus jet aerosol delivery in mechanically ventilated patients
28. Total deposition of aerosol particles in the respiratory tract of children during spontaneous and controlled breathing
29. 2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction
30. Effects of inhaled nitric oxide and nebulized prostacyclin on hypoxic pulmonary vasoconstriction in anesthetized sheep